Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ulcerative Colitis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

103 recruiting trials for Ulcerative Colitis. Eligibility criteria explained in plain English.

TrialFinderData lists 103 Ulcerative Colitis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 55% (21 studies); the largest phase groups are Phase 2: 21, Phase 4: 6, Phase 3: 5, Phase 2 / Phase 3: 2.

Research is led by Tanta University (3), Children's Hospital Medical Center, Cincinnati (2), Takeda (2), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (other, 20 trials), followed by Vedolizumab, ISM5411 tablets.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
103
Total Trials
103
Recruiting Now
5
Phase 3 Trials
10
Sponsors

Track Ulcerative Colitis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04751396

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for...

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1251 location
RECRUITINGNCT04191395

Evolution and Treatments of Chronic Inflammatory Systemic Diseases

Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points....

Sponsor: Centre Hospitalier Universitaire de BesanconEnrolling: 30001 location
RECRUITINGNCT06956703

NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study

The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants. The main question it aims to answer...

Sponsor: University of NottinghamEnrolling: 2401 location
RECRUITINGNCT06780683

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD), which encompasses ulcerative Colitis (UC) and Crohn's Disease (CD), has seen significant improvements in patient outcomes with biologic...

Sponsor: Xiang GaoEnrolling: 1746 locations
RECRUITINGPhase 1 / Phase 2NCT03847467

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF...

Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in...

Sponsor: Children's Hospital Medical Center, CincinnatiEnrolling: 1163 locations
RECRUITINGNCT05698745

Immunological Characteristics of Preclinical IBD

The purpose of this study is to evaluate disease progression, in terms of development of symptomatic disease and complications associated with IBD (e.g. fistula, abscess,...

Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis UlcerosaEnrolling: 45020 locations
RECRUITINGNCT07377188

Pregnancy and Inflammatory Bowel Disease

Inflammatory Bowel disease, including Crohn's disease and Ulcerative Colitis, are chronic diseases. Diagnosis is most often done in women of childbearing age. IBD can have and...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 9451 location
RECRUITINGNCT01731665

Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.

The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of...

Sponsor: Asan Medical CenterEnrolling: 20001 location
RECRUITINGPhase 3NCT06405087

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease...

The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time....

Sponsor: TakedaEnrolling: 7020 locations
RECRUITINGNCT06315179

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation...

Sponsor: Seattle Children's HospitalEnrolling: 2001 location
RECRUITINGPhase 4NCT04999228

Top Down Versus Step up in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis (UC) patients with moderate to severe disease activity at high risk of colectomy. Early use of biologic agents will likely be more effective. But...

Sponsor: Children's Hospital of Fudan UniversityEnrolling: 401 location
RECRUITINGNCT04760964

Mitochondrial DAMPs as Mechanistic Biomarkers of Mucosal Inflammation in Crohn's Disease and Ulcerative Colitis

The MUSIC study is a multi-centre, longitudinal study set in the real world IBD clinical setting to investigate and develop a new biomarker approach that aims to inform both...

Sponsor: University of EdinburghEnrolling: 2503 locations
RECRUITINGPhase 2NCT06309472

Trial of Mirtazapine for Depression in IBD

This study will test whether it is feasible to conduct a clinical trial of mirtazapine (an antidepressant tablet) in patients who have both depression and inflammatory bowel...

Sponsor: King's College LondonEnrolling: 764 locations
RECRUITINGPhase 4NCT04314375

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric...

This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for...

Sponsor: Bausch Health Americas, Inc.Enrolling: 704 locations
RECRUITINGNCT05496348

Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will...

Sponsor: AbbVieEnrolling: 40020 locations
RECRUITINGNCT07385807

Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy...

The goal of this prospective longitudinal cohort study is to examine how the human microbiome of pregnant women-including bacteria and fungi in the gastrointestinal tract, vaginal...

Sponsor: University of British ColumbiaEnrolling: 802 locations
RECRUITINGPhase 3NCT06660693

Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by...

Sponsor: McMaster UniversityEnrolling: 1341 location
RECRUITINGPhase 3NCT03843385

Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis

FRESCO is a randomized, longitudinal, prospective, three arm, multicentre, double blind study to determine safety and efficacy of repeated faecal microbiota transplantation (FMT)...

Sponsor: Andreas StallmachEnrolling: 12920 locations
RECRUITINGNCT06995170

Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With...

Inflammatory Bowel Disease (IBD), encompassing Ulcerative Colitis (UC) and Crohn's Disease (CD), significantly impairs patients' quality of life. Current monitoring of disease...

Sponsor: Xijing HospitalEnrolling: 1461 location
RECRUITINGNCT07245394

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD)...

Sponsor: TIDHI Innovation Inc.Enrolling: 2009 locations
RECRUITINGNCT06095596

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

It's of great importance to effectively induce and maintain disease remission in patients with moderate to severe ulcerative colitis (UC). Vedolizumab (VDZ) is known for its high...

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen UniversityEnrolling: 3341 location
RECRUITINGPhase 4NCT07303686

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative...

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreEnrolling: 1151 location
RECRUITINGPhase 2NCT06213857

Beneficial Effect of Silymarin in Ulcerative Colitis

The goal of this clinical trial is to evaluate the possible beneficial effect of silymarin in Ulcerative Colitis adult patients receiving mesalamine. This is trial that will be...

Sponsor: Tanta UniversityEnrolling: 442 locations
RECRUITINGNCT06971627

Telehealth Monitoring in Inflammatory Bowel Disease: Effects on Medication Compliance, Self-Efficacy, and Quality of...

This randomized controlled trial aims to evaluate the effect of nurse-led telehealth monitoring on medication adherence, self-efficacy, and quality of life in individuals with...

Sponsor: Istanbul University - CerrahpasaEnrolling: 1201 location
RECRUITINGPhase 2 / Phase 3NCT06604273

Unravelling Intestinal Fibrosis in Ulcerative Colitis

The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo...

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Enrolling: 101 location
RECRUITINGNCT04908644

MS-20 on Patients With Ulcerative Colitis(UC)

This is a small pilot study of the fermented soybean extract MicrSoy-20(MS-20) to confirm its ability to improve UC severity with the treatment of standard therapies. The primary...

Sponsor: National Taiwan University HospitalEnrolling: 401 location
RECRUITINGNCT07529236

Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to...

Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). They cause abdominal pain and chronic diarrhea and/or rectal bleeding, which can lead...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 401 location
RECRUITINGPhase 3NCT07577856

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to...

Sponsor: Janssen Research & Development, LLCEnrolling: 6446 locations
RECRUITINGNCT06642883

Evaluation of ProLife 10 FORTE on Gut Microbiota Composition in UC Patients

This clinical trial aims to learn if the probiotic Prolife 10 Forte could improve the Gut Microbiota composition of Ulcerative colitis patients during the remission phase. The...

Sponsor: University of PadovaEnrolling: 701 location
RECRUITINGNCT06896305

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective,...

This clinical study protocol aims to prospectively compare the efficacy of standard therapy with anti-TNF agents combined with the Crohn's Disease Exclusion Diet (CDED) versus...

Sponsor: IRCCS Ospedale San RaffaeleEnrolling: 801 location
RECRUITINGPhase 2NCT05287126

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in...

Sponsor: PfizerEnrolling: 3620 locations
RECRUITINGPhase 2NCT06598943

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis...

Sponsor: Eli Lilly and CompanyEnrolling: 14020 locations
RECRUITINGPhase 2NCT07229950

A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With...

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial comprising screening period, treatment period, and follow-up period. This phase 2 study is...

Sponsor: Shandong Suncadia Medicine Co., Ltd.Enrolling: 481 location
RECRUITINGNCT07532213

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting....

Sponsor: Janssen-Cilag A.G., SwitzerlandEnrolling: 501 location
RECRUITINGPhase 2NCT05327790

LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.

Sponsor: University of AlbertaEnrolling: 401 location
RECRUITINGNCT04030676

QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV)...

Sponsor: Centre Hospitalier Universitaire de Saint EtienneEnrolling: 1962 locations
RECRUITINGNCT05628701

Colectomy Reconstruction for Ulcerative Colitis, Ileorectal Anastomosis vs Ileal Pouch-Anal Anastomosis in Ulcerative...

Background There are no prospective trials comparing the two main reconstructive options after colectomy for Ulcerative colitis, ileal pouch anal anastomosis and ileorectal...

Sponsor: Linkoeping UniversityEnrolling: 1004 locations
RECRUITINGNCT06810518

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a...

Sponsor: American Laboratory Products CompanyEnrolling: 2203 locations
RECRUITINGNCT06691061

The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed...

Sponsor: Humanitas Clinical and Research CenterEnrolling: 4501 location
RECRUITINGPhase 2NCT07300553

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) often leads to poor disease control and reduced quality of life. Changes in the gut microbiota may disrupt the energy metabolism of immune cells,...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 451 location
RECRUITINGNCT06895252

A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly...

Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum, characterized by mucosal inflammation and symptomslike diarrhea, abdominal pain, and...

Sponsor: All India Institute of Medical SciencesEnrolling: 2206 locations
RECRUITINGPhase 2NCT07035041

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis....

Sponsor: InventisBio Co., LtdEnrolling: 1201 location
RECRUITINGNCT07380022

Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB...

The primary objective of the present postdoctoral research is to evaluate the acceptability and adherence of two dietary supplements containing microbial phytase, Goodphyte IB...

Sponsor: University of ThessalyEnrolling: 1001 location
RECRUITINGNCT07243639

Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis

Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course,...

Sponsor: Showa Inan General HospitalEnrolling: 301 location
RECRUITINGPhase 2NCT06029972

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative...

Sponsor: Gilead SciencesEnrolling: 17620 locations
RECRUITINGPhase 2NCT07113522

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study...

Sponsor: Mirador Therapeutics, Inc.Enrolling: 14020 locations
RECRUITINGPhase 2NCT07265570

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients...

Sponsor: InSilico Medicine Hong Kong LimitedEnrolling: 8020 locations
RECRUITINGNCT05456893

A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted...

UC is a chronic, idiopathic form of intestinal inflammatory disease (IBD) that affects the colon, most commonly afflicting adults aged 30-40 years and resulting in disability and...

Sponsor: Central Hospital, Nancy, FranceEnrolling: 951 location
RECRUITINGPhase 2NCT07012395

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is...

Sponsor: Spyre Therapeutics, Inc.Enrolling: 64520 locations
RECRUITINGNCT06515210

Personalized Anti-Inflammatory Fibres in Ulcerative Colitis

The goal of this clinical trial is to determine the clinical effects of two different dietary fibre supplements, acacia gum (AG) and microcrystalline cellulose (MCC), in patients...

Sponsor: University of AlbertaEnrolling: 691 location

Showing 50 of 103 trials.Search all Ulcerative Colitis trials

Frequently Asked Questions

There are currently 103 clinical trials for Ulcerative Colitis, with 103 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Ulcerative Colitis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 5 Phase 3 trials for Ulcerative Colitis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.